NYSE: OGN INVESTOR ALERT: Berger Montague Advises Organon & Co. (NYSE: OGN) Investors of July 22, 2025 Deadline

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for alleged misrepresentation regarding its capital allocation priorities following the acquisition of Dermavant [1][3]. Company Overview - Organon & Co. is a healthcare company focused on women's health, headquartered in Jersey City, NJ [2]. - In October 2024, Organon acquired Dermavant, a biopharmaceutical company, for $1.2 billion [2]. Lawsuit Details - The lawsuit claims that despite increasing debt from the Dermavant acquisition, Organon assured investors it would maintain its dividend as its "1 capital allocation priority" [3]. - The suit alleges that after the acquisition, Organon shifted its capital allocation focus to debt reduction instead of maintaining dividend payouts [3]. Dividend Announcement - On May 1, 2025, Organon announced a significant reduction in its dividend payout from$0.28 per share to $0.02 per share, stating that returning capital to shareholders was a lower priority [4]. - Following this announcement, Organon's stock price fell by$3.48 per share, approximately 27%, from $12.93 on April 30, 2025, to$9.45 on May 1, 2025 [4].